via CDC
A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
Learn more: Researchers develop a novel RNA-based therapy to target West Nile Virus
The Latest on: RNA therapy
via Google News
The Latest on: RNA therapy
- Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs Development Analysis Report 2022 - ResearchAndMarkets.comon May 17, 2022 at 2:06 am
The "Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ...
- Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdownon May 16, 2022 at 4:48 am
Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 - WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Dyne ...
- Orna Therapeutics Announces First-in-Class, Breakthrough Data Demonstrating Potential of Circular RNA Platform at ASGCT 2022on May 16, 2022 at 3:08 am
Advances in oRNA expression and delivery enable pipeline of therapeutics across a diverse range of disease areasLead isCAR program shows ...
- Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravison May 10, 2022 at 5:19 am
Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia and Related Disorders in Miami- "I am very encouraged by the interim analysis findings ...
- Outlook on the RNA Based Therapeutic Global Market to 2030 - Multifactorial Disease Targeting Presents Opportunitieson April 28, 2022 at 3:47 am
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "RNA Based Therapeutic Market by Disease Type, Application and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has ...
- Outlook on the RNA Based Therapeutic Global Market to 2030 - Multifactorial Disease Targeting Presents Opportunitieson April 27, 2022 at 11:43 pm
In addition, messenger RNA (mRNA) can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins, such as cystic fibrosis. Moreover, Prominent ...
- How the Covid jab technology could help cut your cholesterolon April 27, 2022 at 5:12 pm
Both Pfizer and Moderna Covid-19 vaccines are made using RNA. RNA gene therapy cleverly alters instructions to the body's cells so that they make specific proteins that perform a useful function.
- The Worldwide RNA Based Therapeutic Industry is Expected to Reach $25 Billion by 2030on April 27, 2022 at 1:09 pm
The global RNA based therapeutics market generated in 2021, and is projected to reach by 2030, growing at a CAGR of 17.6% from 2021 to 2030. RNA based therapeutics is a class of medications based ...
- The Worldwide RNA Based Therapeutic Industry is Expected to Reach $25 Billion by 2030on April 27, 2022 at 12:47 pm
In addition, messenger RNA (mRNA) can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins, such as cystic fibrosis. Moreover, Prominent ...
via Bing News